Tag: Pharmaceutical supply chain

In the United States, approximately 30.6 million adults report using benzodiazepines like clonazepam [1.7.2]. As of 2025, the question 'Is there a shortage of clonazepam?' has become a critical concern for many, with some manufacturers reporting supply issues due to increased demand [1.2.1].

The discontinuation of fluphenazine decanoate (Modecate) around 2018 was primarily due to manufacturing difficulties and unpredictable supplies of its active pharmaceutical ingredient [1.2.2, 1.4.3]. This article delves into why was fluphenazine discontinued and the impact on patients.

The number of drug shortages in the U.S. is at its highest since 2001, affecting numerous critical medications. The ongoing triamcinolone backorder is a prime example of this widespread issue, with various manufacturers facing challenges that disrupt the supply chain and impact patient care.

According to the American Society of Health-System Pharmacists (ASHP), the number of active drug shortages in the U.S. remains critically high, with the shortage of essential medications like morphine being a persistent issue. Understanding why there is a shortage of morphine requires examining a complex interplay of manufacturing challenges, market economics, and stringent regulatory controls.

In late 2024, the manufacturer Thornton & Ross confirmed the discontinuation of the popular Metanium Nappy Rash Ointment. The decision, which sparked concern among parents, was a direct result of supply chain constraints affecting a key pharmaceutical ingredient.